Calibration of diodes for in vivo dosimetry in breast treatments delivered using a sliding window IMRT technique requires non-linear CFs. Setting the calibration geometry close to the average irradiation geometry minimizes the value and uncertainty of CFs. We recommend two or more detectors per field, placed on high-fluence regions, to avoid false-positive warnings due to variations of MLC transmission. This work was funded by a grant from the Barcelona
Purpose/Objective: In our institution, almost all external beam radiotherapy treatments are verified using in vivo portal dosimetry, for reasons of efficiency and patient safety. Deviations between planned and EPID reconstructed dose occur mainly due to three causes: dose reconstruction model limitations, patient related causes and external factors. The aims of this work are: 1) to quantify the alert rate per treatment site, 2) to classify alerts according to the three abovementioned causes and 3) to prioritize improvement of our method. Materials and Methods: Portal images are converted to a 3D patient dose distribution by means of a simple backprojection model and the planning CT, and compared to the planned dose distribution by means of 3D gamma evaluation (default 3%, 3mm). Criteria are based on mean γ (γ mean ), 1% maximum γ (γ 1% ), percentage γ<1 (P γ<1 ) and dose difference at the dose reconstruction point (DRP) (ΔD DRP ). For IMRT/VMAT 3 different criteria levels are applied: (a) default: γ mean < 0.5, γ 1% < 2, P γ<1 > 85%, ΔD DRP < 3%, (b) breast: γ mean < 1.4, γ 1% < 5, P γ<1 > 50%, ΔD DRP < 3%, (c) GE and H&N: γ mean < 0.7, γ 1% < 2.5, P γ<1 > 80%, ΔD DRP < 4%. Non-IMRT treatments (mostly palliative) use (9%, 3mm) gamma parameters and γ mean < 0.9, ΔD DRP < 10% as alert criteria. The causes of deviation of all alerts from 2013 have been indicated by an experienced medial physicist. Alerts that resulted in clinical intervention were excluded (18 cases). The classification was done using information in the R&V system, anatomical information from CBCT, and the original comments when the alert was first reviewed clinically. Results: Table 1 shows the number of alerts per treatment site and assigned sources of deviation. 1397 out of 5766 verified plans were alerted (24%). Model limitations, patient related causes and external sources gave rise to false positive alerts in 1107 (19%), 557 (10%) and 101 cases (2%), respectively. In spite of less strict criteria, the alert rate in breast treatments is still 33%. This treatment site suffers from the absence of missing tissue compensation in our model and a well-known problem with transit dosimetry: setup errors (offline setup protocol). In addition, the use of bolus material in treatment planning is incompatible with portal dosimetry, contributing considerably to the alert rate. In all treatments, an unfavorable choice of the dose reference point location (e.g., on a high dose gradient) is an important cause of alerts. The impact of anatomy changes on portal dosimetry results is a topic of current research. Conclusions: 76% of in vivo portal dosimetry results is within criteria. Limitations of the back-projection model are the main source of alerts. In 10% of plans an alert is caused by patient setup and anatomy changes. This can be regarded as the baseline alert rate for in vivo portal dosimetry using the current criteria. Efforts to decrease the alert rate should focus on breast treatments, handling inhomogeneities and choice of dose reconstruction point.
EP-1417
Is a decrease in dose rate in a kilovoltage X-ray radiotherapy unit directly linked to tube metallization? M. Lizondo 1 , A. Latorre-Mussol 1 , A. Ruiz 1 , N. Jornet 1 , T. Eudaldo 1 , P. Carrasco 1 , O. Jordi 1 , P. Delgado 1 , M. Ribas 1 1 Hospital de la Santa Creu i Sant Pau, Servei de Radiofísica i Radioprotecció, Barcelona, Spain Purpose/Objective: Kilovoltage x-ray radiotherapy units play an important role in skin cancer treatment. Over the last ten years, our QA programme has shown a decrease in dose rate in our Therapax SXT 150 (Pantak Seifert) unit. We studied whether tube metallization could explain this variation in dose rate by comparing our QA records with simulated data. Materials and Methods: The Therapax SXT 150 has a metalceramic x-ray tube (MXR-161) and provides 8 beam qualities ranging from 50kV, 0.45 mm Al HVL (lowest beam quality) to 150 kV, 1.48 mm Cu HVL. A set of applicators defines circular field sizes with diameters ranging from 1 to 15 cm. The QA programme for this unit, based on IAEA TECDOC-1151 (and TRS-398 for absorbed dose D w determination), quarterly assesses the constancy of: D w rate, HVL, quality index QI (defined as the ratio of absorbed doses at two fixed depths), output factors, field size, symmetry, homogeneity, timer reproducibility and linearity and time error. Following this QA program, over the last ten years, we observed a decrease in D w rate from 7 to 15%, depending on beam quality. To evaluate the relationship between the variations of D w rate, HVL and QI, we adopted two approaches. First, we analysed these parameters from our QA records. Second, we simulated tube metallization using XCompW v.0.11.0 (R. Nowotny, Med Univ Wien) by adding tungsten filtration ranging from 0.04 to 0.14 mm W. We then calculated D w rate and HVL. To validate the simulation, we measured D w rate, HVL and QI adding aluminium foils (tungsten was not available) with thicknesses ranging from 0.05 to 0.15 mm Al at the exit of the tube window. We then compared these experimental data with a simulation using aluminium filtration. Results: Table 1 shows QA records were highly constant. No changes were observed for HVL (0±5%) or QI (0.9±1.0%). HVL variability was greater than QI variability due to measurement inaccuracies. Technical service reports showed that tube current and high voltage did not vary over 10 years. However, D w rate decreased to 15% for the lowest beam quality (figure 1a). Figure 1b shows that simulations using aluminium were compatible with the experimental results. To decrease D w rate to 15%, we needed an additional filtration of 0.087 mm Al for the experiment and 0.078 mm Al for the simulation. In this setting, HVL increased to 17.9% and 17.6%, respectively, which validates the simulation method. We also found QI increased to 10.5% in our experiment. The simulation using tungsten shows that we would need an additional filtration of 0.764 mm W to decrease D w rate to 15%, but then HVL would increase to 10.3%, which is not observed in our QA records.
Conclusions:
Tube metallization causes a variation of the same magnitude (in %) for D w rate, HVL and QI. According to our QA records, the decrease in D w rate is not due to metallization but to x-ray tube aging. We recommend monitoring beam quality using QI instead of HVL, because although sensitivity is similar, QI is a more accurate measurement.
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Adapting Gafchromic EBT3 Film to Tomotherapy Patient Specific QA process A. Kapulsky 1 , D.F. Lewis 2 , A.M. Ndlovu 1 1 Hackensack University Medical Center, Medical Physics, Hackensack, USA 2 RCF Counsulting LLC, Physics, Hartford, USA Purpose/Objective: While EDR2 film dosimetry using a VIDAR scanner is widely used in the Tomotherapy patient specific QA process, self developing GAFchromic films eliminate the need for a film processor and speed up plan-film analysis. We propose a method of using FilmQAPro software (Ashland, Inc) with the additional spatial non uniformity correction in conjunction with Tomotherapy's own plan-film analysis module. Materials and Methods: GAFchromic EBT3 (Ashland, Inc.) and EDR2 films were irradiated on a Tomotherapy HI-Art system ( Accuray, inc.) to deliver treatment plans to Tomotherapy phantom. Calibration films were irradiated to known doses on a V21 EX linear accelerator (Varian, Inc). Films were scanned on Vidar Dosimetry Pro Advantage and flatbed EPSON 10000 scanners.
